- Home
- EVGO vs NGEN Comparison
EVGO vs NGEN Comparison
Compare EVGO & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVGO | NGEN |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | Canada |
| Employees | 331 | 14 |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 337.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EVGO | NGEN |
|---|---|---|
| Price | $2.16 | $3.93 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.23 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 230.9K |
| Earning Date | 05-06-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.45 | N/A |
| Revenue Next Year | $29.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $3.51 |
| 52 Week High | $5.18 | $5.93 |
Technical Indicators
Market Signals| Indicator | EVGO | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 45.17 |
| Support Level | $1.64 | $3.65 |
| Resistance Level | $2.30 | $4.52 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 66.98 | 22.22 |
Price Performance
Historical ComparisonAbout EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.